Related Experiment Video
Updated: Feb 2, 2026
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines
Ajimu Keremu1, Abudusaimi Aimaiti2, Zhilin Liang1
1Orthopedic Center, First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar, 844000, Xinjiang, People's Republic of China.
Abstract:
Histone deacetylases (HDACs), initially described as histone modifiers, have more recently been verified to target various other proteins unrelated to the chromatin environment. On this basis, findings of the current study demonstrates that the pharmacological or genetic abrogation of HDAC6 in osteosarcoma cell lines down-regulates the expression of program death receptor ligand-1 (PD-L1), an important co-stimulatory molecule expressed in cancer cells, which activates the inhibitory regulatory pathway PD-1 in T cells. As shown by our results, the mechanism by which HDAC6 regulated PD-L1 expression was mediated by the transcription factor STAT3. In addition, we observed that selective HDAC6 inhibitors could inhibit tumor progression in vivo. Crucially, these results provide an essential pre-clinical rationale and justification for the necessity of further research on HDAC6 inhibitors as potential immuno-modulatory agents in osteosarcoma.
Insights
Histone deacetylase 6 (HDAC6) inhibition down-regulates PD-L1 in osteosarcoma, offering a potential new immunotherapy strategy. Selective HDAC6 inhibitors show promise in slowing tumor growth, warranting further investigation.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Histone deacetylases (HDACs) are enzymes with roles beyond chromatin modification.
- HDAC6 targets non-histone proteins, influencing various cellular processes.
- Program death receptor ligand-1 (PD-L1) is crucial in cancer immune evasion.
Purpose of the Study:
- To investigate the role of HDAC6 in regulating PD-L1 expression in osteosarcoma.
- To explore the therapeutic potential of HDAC6 inhibitors in osteosarcoma treatment.
Main Methods:
- Utilized pharmacological and genetic methods to abrogate HDAC6 in osteosarcoma cell lines.
- Investigated the downstream effects on PD-L1 expression and its regulatory mechanisms.
- Assessed the efficacy of selective HDAC6 inhibitors in preclinical in vivo models.
Main Results:
- HDAC6 abrogation significantly down-regulated PD-L1 expression in osteosarcoma cells.
- The STAT3 transcription factor was identified as the mediator of HDAC6's regulation of PD-L1.
- Selective HDAC6 inhibitors demonstrated efficacy in inhibiting osteosarcoma tumor progression in vivo.
Conclusions:
- HDAC6 plays a critical role in regulating PD-L1 expression in osteosarcoma.
- Targeting HDAC6 offers a promising strategy for modulating the tumor immune microenvironment.
- HDAC6 inhibitors represent a potential therapeutic avenue for osteosarcoma immunotherapy.
Related Concept Videos
01:17Role of ER in the Secretory Pathway
Components of the secretory pathway
About a third of proteins synthesized in the cell are sorted via the secretory route. They shuffle between different compartments in membrane-bound vesicles until they reach their final destination. The main intracellular compartments involved...
02:24Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
02:24Regulation of Expression Occurs at Multiple Steps
01:16Cell Lines
01:23Regulation of Expression at Multiple Steps
01:27Constitutive and Regulated Gene Expression